Literature DB >> 33745993

Modification of Pathologic T Classification for Non-small Cell Lung Cancer With Visceral Pleural Invasion: Data From 1,055 Cases of Cancers ≤ 3 cm.

Run-Bin Liang1, Peng Li2, Bob T Li3, Jie-Tian Jin2, Valerie W Rusch4, David R Jones4, Yi-Long Wu5, Qing Liu6, Jie Yang7, Mu-Zi Yang8, Shuo Li1, Hao Long1, Jian-Hua Fu1, Lan-Jun Zhang1, Peng Lin1, Tie-Hua Rong1, Xue Hou9, Su-Xia Lin2, Hao-Xian Yang10.   

Abstract

BACKGROUND: Visceral pleural invasion (VPI) with PL1 or PL2 increases the T classification from T1 to T2 in non-small cell lung cancers (NSCLCs) ≤ 3 cm. We proposed a modified T classification based on VPI to guide adjuvant therapy. RESEARCH QUESTION: Is it reasonable to upstage PL1-positive cases from T1 to T2 for NSCLCs ≤ 3 cm? STUDY DESIGN AND METHODS: In total, 1,055 patients with resected NSCLC were retrospectively included. Tumor sections were restained with hematoxylin and eosin stain and Victoria blue elastic stain for the elastic layer. Disease-free survival (DFS) and overall survival (OS) were calculated by the Kaplan-Meier method. Subgroup analysis and a Cox proportional hazards model were used to further determine the impact of VPI on survival.
RESULTS: The extent of VPI was diagnosed as PL0 in 824 patients, PL1 in 133 patients, and PL2 in 98 patients. The 5-year DFS rates of patients with PL0, PL1, and PL2 were 62.6%, 60.2%, and 28.8% (P < .01), whereas the corresponding 5-year OS rates were 78.6%, 74.4%, and 50.0% (P < .01), respectively. As predicted, the DFS and OS of patients with PL2 were much worse than those of patients with PL0 (P < .01) and PL1 (P < .01). However, both the DFS and OS of patients with PL0 and PL1 were comparable (DFS: P = .198; OS: P = .150). For node-negative cases, the DFS and OS of patients with PL0 and PL1 were also comparable (DFS: P = .468; OS: P = .388), but patients with PL2 had much worse DFS and OS than patients with PL0 (P < .01) and PL1 (P < .01). Multivariable analyses suggested that PL2, together with node positivity and poor cell differentiation, was an independent adverse prognostic factor.
INTERPRETATION: In NSCLCs ≤ 3 cm, tumors with PL1 should remain defined as T1, not T2. Overtreatment by adjuvant chemotherapy in node-negative NSCLCs ≤ 3 cm might be avoided in PL1 cases.
Copyright © 2021 American College of Chest Physicians. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  non-small cell lung cancer; prognosis; staging; visceral pleural invasion

Mesh:

Year:  2021        PMID: 33745993      PMCID: PMC8449009          DOI: 10.1016/j.chest.2021.03.022

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  30 in total

1.  Subcategorization of lung cancer based on tumor size and degree of visceral pleural invasion.

Authors:  Noriaki Sakakura; Shoichi Mori; Katsuhiro Okuda; Takayuki Fukui; Shunzo Hatooka; Masayuki Shinoda; Keitaro Matsuo; Yasushi Yatabe; Kohei Yokoi; Tetsuya Mitsudomi
Journal:  Ann Thorac Surg       Date:  2008-10       Impact factor: 4.330

2.  Surgical results and prognostic factors in early non-small cell lung cancer.

Authors:  J Padilla; V Calvo; J C Peñalver; G Sales; A Morcillo
Journal:  Ann Thorac Surg       Date:  1997-02       Impact factor: 4.330

3.  The IASLC Lung Cancer Staging Project: Proposals for the Revisions of the T Descriptors in the Forthcoming Eighth Edition of the TNM Classification for Lung Cancer.

Authors:  Ramón Rami-Porta; Vanessa Bolejack; John Crowley; David Ball; Jhingook Kim; Gustavo Lyons; Thomas Rice; Kenji Suzuki; Charles F Thomas; William D Travis; Yi-Long Wu
Journal:  J Thorac Oncol       Date:  2015-07       Impact factor: 15.609

Review 4.  Adjuvant Systemic Therapy and Adjuvant Radiation Therapy for Stage I to IIIA Completely Resected Non-Small-Cell Lung Cancers: American Society of Clinical Oncology/Cancer Care Ontario Clinical Practice Guideline Update.

Authors:  Mark G Kris; Laurie E Gaspar; Jamie E Chaft; Erin B Kennedy; Christopher G Azzoli; Peter M Ellis; Steven H Lin; Harvey I Pass; Rahul Seth; Frances A Shepherd; David R Spigel; John R Strawn; Yee C Ung; Michael Weyant
Journal:  J Clin Oncol       Date:  2017-04-24       Impact factor: 44.544

5.  Visceral pleural invasion: pathologic criteria and use of elastic stains: proposal for the 7th edition of the TNM classification for lung cancer.

Authors:  William D Travis; Elisabeth Brambilla; Ramon Rami-Porta; Eric Vallières; Masahiro Tsuboi; Valerie Rusch; Peter Goldstraw
Journal:  J Thorac Oncol       Date:  2008-12       Impact factor: 15.609

6.  Visceral pleural involvement in nonsmall cell lung cancer: prognostic significance.

Authors:  Toshihiro Osaki; Akira Nagashima; Takashi Yoshimatsu; Sosuke Yamada; Kosei Yasumoto
Journal:  Ann Thorac Surg       Date:  2004-05       Impact factor: 4.330

7.  Visceral pleural invasion classification in non-small-cell lung cancer in the 7th edition of the tumor, node, metastasis classification for lung cancer: validation analysis based on a large-scale nationwide database.

Authors:  Akikazu Kawase; Junji Yoshida; Etsuo Miyaoka; Hisao Asamura; Yoshitaka Fujii; Yoichi Nakanishi; Kenji Eguchi; Masaki Mori; Noriyoshi Sawabata; Meinoshin Okumura; Kohei Yokoi
Journal:  J Thorac Oncol       Date:  2013-05       Impact factor: 15.609

8.  Visceral pleural invasion classification in non-small cell lung cancer: a proposal on the basis of outcome assessment.

Authors:  Kimihiro Shimizu; Junji Yoshida; Kanji Nagai; Mitsuyo Nishimura; Tomoyuki Yokose; Genichiro Ishii; Yutaka Nishiwaki
Journal:  J Thorac Cardiovasc Surg       Date:  2004-06       Impact factor: 5.209

9.  The incidence and distribution of mediastinal lymph node metastasis and its impact on survival in patients with non-small-cell lung cancers 3 cm or less: data from 2292 cases.

Authors:  Mu-Zi Yang; Xue Hou; Run-Bin Liang; Ren-Chun Lai; Jie Yang; Shuo Li; Hao Long; Jian-Hua Fu; Peng Lin; Xin Wang; Tie-Hua Rong; Hao-Xian Yang
Journal:  Eur J Cardiothorac Surg       Date:  2019-07-01       Impact factor: 4.191

Review 10.  The present status of postoperative adjuvant chemotherapy for completely resected non-small cell lung cancer.

Authors:  Masahiro Tsuboi; Tatsuo Ohira; Hisashi Saji; Kuniharu Miyajima; Naohiro Kajiwara; Osamu Uchida; Jitsuo Usuda; Harubumi Kato
Journal:  Ann Thorac Cardiovasc Surg       Date:  2007-04       Impact factor: 1.520

View more
  3 in total

1.  Is lobectomy superior to sub-lobectomy in non-small cell lung cancer with pleural invasion? A population-based competing risk analysis.

Authors:  Xue Song; Yangyang Xie; Yurou Zhu; Yafang Lou
Journal:  BMC Cancer       Date:  2022-05-13       Impact factor: 4.638

2.  Treatment Modality for Stage IB Peripheral Non-Small Cell Lung Cancer With Visceral Pleural Invasion and ≤3 cm in Size.

Authors:  Weijia Huang; Han-Yu Deng; Ming-Ying Lin; Kai Xu; Yu-Xiao Zhang; Chi Yuan; Qinghua Zhou
Journal:  Front Oncol       Date:  2022-02-18       Impact factor: 6.244

3.  Rethinking the Selection of Pathological T-Classification for Non-Small-Cell Lung Cancer in Varying Degrees of Visceral Pleural Invasion: A SEER-Based Study.

Authors:  Pu Fang; Jiayi Cheng; Youjin Lu; Lin Fu
Journal:  Front Surg       Date:  2022-05-19
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.